### 2.2.1	In vitro / physicochemical data

A literature search was carried out to collect available information on physicochemical properties of eryhtromycin. The obtained information from the literature is summarized in the table below and is used for model building.

| **Parameter**                                | **Unit** | **Literature**                                               | **Description**                                  |
| :------------------------------------------- | -------- | ------------------------------------------------------------ | ------------------------------------------------ |
| Molecular weight                             | g/mol    | 733.9 ([drugbank.ca](# 5 References))                        | Molecular weight                                 |
| pK<sub>a</sub> (basic)                       |          | 8.8 ([Lien 1974](# 5 References)); 8.88 ([McFarland 1997](# 5 References)) | Acid dissociation constant                       |
| logP                                         |          | 2.48 ([Lien 1974](# 5 References)); 2.92 ([Capobianco 1994](# 5 References)); 3.06 ([McFarland 1997](# 5 References)) | Partition coefficient between octanol and water  |
| f<sub>u</sub>                                |          | 0.27 ± 0.05<sup>a</sup> ([Sun 2010](# 5 References)); 0.28 ± 0.04<sup>a</sup> ([Iliopoulou 1982](# 5 References)); 0.305 ± 0.028<sup>a</sup> ([Barre 1987](# 5 References)); 0.326 ([Xu 2009](# 5 References)) | Fraction unbound in human plasma                 |
| Water solubility (erythromycin lactobionate) | mg/L     | 200000 ([U.S. Patent 2,761,859](# 5 References))             | Solubility of erythromycin lactobionate in water |
| Water solubility (erythromycin stearate)     | mg/L     | 182 ([Jones 1969](# 5 References))                           | Solubility of erythromycin stearate in water     |
| Water solubility (erythromycin base)         | mg/L     | 2100 ([Manna 1998](# 5 References))                          | Solubility of free erythromycin as base in water |

 <sup>a</sup> mean ± SD

### 2.2.2	In vitro data on mechanism-based inhibition of CYP3A

A literature search was carried out to collect quantitative information the meachnism-based inhibition of CYP3A by erythromycin, in particular measured values for K<sub>I</sub> and k<sub>inact</sub>. The gathered information is summarized in the table below and is used for model building.

| Victim   compound | In   vitro system | Enzyme | K<sub>I</sub>   [µM] | k<sub>inact</sub>   [min<sup>-1</sup>] | Concentration   range of erythromycin [µM] | Concentration   of victim compound [µM] | Reference                           |
| ----------------- | ----------------- | ------ | -------------------- | -------------------------------------- | ------------------------------------------ | --------------------------------------- | ----------------------------------- |
| testosterone      | rec cDNA CYP3A4   | CYP3A4 | 1.04                 | 0.0293                                 | 0 - 20                                     | 100                                     | [Akiyoshi 2013](# 5 References)     |
| testosterone      | rec cDNA CYP3A4   | CYP3A4 | 1.21                 | 0.0164                                 | 0 - 20                                     | 100                                     | [Akiyoshi 2013](# 5 References)     |
| testosterone      | rec cDNA CYP3A4   | CYP3A4 | 0.415                | 0.0159                                 | 0 - 20                                     | 100                                     | [Akiyoshi 2013](# 5 References)     |
| testosterone      | rec cDNA CYP3A4   | CYP3A4 | 2.24                 | 0.0293                                 | 0 - 20                                     | 100                                     | [Akiyoshi 2013](# 5 References)     |
| testosterone      | rec cDNA CYP3A4   | CYP3A4 | 0.753                | 0.0248                                 | 0 - 20                                     | 100                                     | [Akiyoshi 2013](# 5 References)     |
| midazolam         | rec cDNA CYP3A4   | CYP3A  | 9.5                  | 0.16                                   | 50-fold range                              | 10                                      | [Atkinson 2005](# 5 References)     |
| midazolam         | rec cDNA CYP3A4   | CYP3A  | 8.82                 | 0.12                                   | 50-fold range                              | 10                                      | [Atkinson 2005](# 5 References)     |
| midazolam         | rec cDNA CYP3A4   | CYP3A  | 8.3                  | 0.09                                   | 50-fold range                              | 10                                      | [Atkinson 2005](# 5 References)     |
| testosterone      | rec cDNA CYP3A4   | CYP3A  | 9.5                  | 0.06                                   | 4 - 200                                    | 16.7                                    | [Atkinson 2005](# 5 References)     |
| triazolam         | HLM               | CYP3A  | 5.4                  | 0.069                                  |                                            | 400                                     | [Aueviriyavit 2010](# 5 References) |
| testosterone      | rec cDNA CYP3A4   | CYP3A4 | 5.3                  | 0.12                                   | 5 - 20                                     | 200                                     | [Chan 2000](# 5 References)         |
| midazolam         | cryopreserved HEP | CYP3A  | 60                   | 0.081                                  | 3 - 300                                    | 30                                      | [Chen 2011](# 5 References)         |
| midazolam         | cryopreserved HEP | CYP3A  | 67.9                 | 0.079                                  | 3 - 300                                    | 30                                      | [Chen 2011](# 5 References)         |
| midazolam         | rec cDNA CYP3A4   | CYP3A4 | 0.762                | 0.0648                                 | 0.1 - 30                                   | 4                                       | [Ishikawa 2017](# 5 References)     |
| testosterone      | rec cDNA CYP3A4   | CYP3A4 | 1.00                 | 0.0604                                 | 0.1 - 30                                   | 150                                     | [Ishikawa 2017](# 5 References)     |
| nifedipine        | rec cDNA CYP3A4   | CYP3A4 | 0.794                | 0.0766                                 | 0.1 - 30                                   | 6                                       | [Ishikawa 2017](# 5 References)     |
| triazolam         | HLM               | CYP3A4 | 15.9                 | 0.062                                  | 3 - 100                                    | 300                                     | [Kanamitsu 2000](# 5 References)    |
| triazolam         | HLM               | CYP3A4 | 17.4                 | 0.055                                  | 3 - 100                                    | 300                                     | [Kanamitsu 2000](# 5 References)    |
| triazolam         | rec cDNA CYP3A4   | CYP3A4 | 19.1                 | 0.173                                  | 3 - 100                                    | 300                                     | [Kanamitsu 2000](# 5 References)    |
| triazolam         | rec cDNA CYP3A4   | CYP3A4 | 18.9                 | 0.097                                  | 3 - 100                                    | 300                                     | [Kanamitsu 2000](# 5 References)    |
| testosterone      | HLM               | CYP3A4 | 29.4                 | 0.0271                                 |                                            | 250                                     | [Kosaka 2017](# 5 References)       |
| testosterone      | HLM               | CYP3A4 | 30                   | 0.040                                  | 0.3 - 300                                  |                                         | [Kozakai 2013](# 5 References)      |
| midazolam         | HLM               | CYP3A4 | 12                   | 0.035                                  | 0.3 - 300                                  |                                         | [Kozakai 2013](# 5 References)      |
| midazolam         | HLM               | CYP3A4 | 20                   | 0.033                                  | 0.3 - 300                                  |                                         | [Kozakai 2013](# 5 References)      |
| midazolam         | cryopreserved HEP | CYP3A  | 25.15                | 0.08                                   | 0.13 - 100                                 | 30                                      | [Mao 2011](# 5 References)          |
| midazolam         | HLM               | CYP3A  | 10.8                 | 0.032                                  |                                            |                                         | [Mao 2016](# 5 References)          |
| midazolam         | cryopreserved HEP | CYP3A  | 30.7                 | 0.05                                   | 0 - 300                                    | 20                                      | [Mao 2016](# 5 References)          |
| midazolam         | cryopreserved HEP | CYP3A  | 59.2                 | 0.062                                  | 0 - 100                                    | 5                                       | [Mao 2016](# 5 References)          |
| midazolam         | cryopreserved HEP | CYP3A  | 80.3                 | 0.052                                  | 0 - 100                                    | 20                                      | [Mao 2016](# 5 References)          |
| midazolam         | rec cDNA CYP3A4   | CYP3A4 | 7.47                 | 0.042                                  | 2 - 50                                     | 8                                       | [McConn 2004](# 5 References)       |
| midazolam         | HLM               | CYP3A4 | 10.9                 | 0.046                                  | 2 - 100                                    | 8                                       | [McConn 2004](# 5 References)       |
| midazolam         | primary HEP       | CYP3A  | 11                   | 0.07                                   | 0.1 - 10                                   | 3                                       | [McGinnity 2006](# 5 References)    |
| midazolam         | HLM               | CYP3A4 | 10                   | 0.036                                  | 0 - 25                                     |                                         | [Obach 2007](# 5 References)        |
| testosterone      | HLM               | CYP3A4 | 9.8                  | 0.039                                  | 0 - 25                                     | 500                                     | [Obach 2007](# 5 References)        |
| testosterone      | rec cDNA CYP3A4   | CYP3A4 | 0.92                 | 0.058                                  | 5 - 100                                    | 250                                     | [Polasek 2006](# 5 References)      |
| testosterone      | HLM               | CYP3A4 | 12.8                 | 0.037                                  | 5 - 100                                    | 250                                     | [Polasek 2006](# 5 References)      |
| midazolam         | rec cDNA CYP3A4   | CYP3A4 | 5.1                  | 0.30                                   | 0.5 - 50                                   | 100                                     | [Ring 2005](# 5 References)         |
| testosterone      | rec cDNA CYP3A4   | CYP3A4 | 0.92                 | 0.058                                  |                                            |                                         | [Teng 2010](# 5 References)         |
| testosterone      | HLM               | CYP3A4 | 4.579                | 0.0115                                 |                                            |                                         | [Teng 2010](# 5 References)         |
| domperidone       | HLM               | CYP3A4 | 18.4                 | 0.022                                  | 2.5 - 200                                  | 500                                     | [Ung 2009](# 5 References)          |
| domperidone       | rec cDNA CYP3A4   | CYP3A4 | 4.1                  | 0.026                                  | 2.5 - 200                                  | 500                                     | [Ung 2009](# 5 References)          |
| midazolam         | HLM               | CYP3A4 | 12.1                 | 0.0215                                 | 0 - 100                                    | 25                                      | [Watanabe 2007](# 5 References)     |
| nifedipine        | HLM               | CYP3A4 | 11.3                 | 0.0295                                 | 0 - 100                                    | 50                                      | [Watanabe 2007](# 5 References)     |
| testosterone      | HLM               | CYP3A4 | 10.9                 | 0.0352                                 | 0 - 100                                    | 200                                     | [Watanabe 2007](# 5 References)     |
| midazolam         | HLM               | CYP3A  | 1.48                 | 0.017                                  | 0.5 - 500                                  | 20                                      | [Xu 2009](# 5 References)           |
| midazolam         | cryopreserved HEP | CYP3A  | 20.0                 | 0.016                                  | 0.5 - 500                                  | 20                                      | [Xu 2009](# 5 References)           |
| midazolam         | cryopreserved HEP | CYP3A  | 109                  | 0.055                                  | 0.5 - 500                                  | 20                                      | [Xu 2009](# 5 References)           |
| midazolam         | HLM               | CYP3A  | 81.8                 | 0.0665                                 | 20 - 400                                   | 10                                      | [Yamano 2001](# 5 References)       |
| midazolam         | HLM               | CYP3A  | 15.7                 | 0.1                                    |                                            |                                         | [Zhang 2006](# 5 References)        |
| testosterone      | rec cDNA CYP3A4   | CYP3A4 | 5                    | 0.34                                   | 1 - 50                                     | 200                                     | [Zhang 2009](# 5 References)        |
| testosterone      | HLM               | CYP3A4 | 15.7                 | 0.09                                   | 1 - 50                                     | 200                                     | [Zhang 2009](# 5 References)        |
| midazolam         | HLM               | CYP3A4 | 26.5                 | 0.041                                  | 2.5 - 50                                   | 10                                      | [Zimmerlin 2011](# 5 References)    |

*Note:* Abbreviations: HEP: human hepatocytes; HLM: human liver microsomes; rec cDNA CYP3A4: human recombinant c-DNA CYP3A4 enzymes (e.g. supersomes, baculovirus-insect cell system, E. coli transfected cells)

### 2.2.3	Clinical data

A literature search was carried out to collect available PK data on erythromycin in healthy adults. 

The following publications were found and used for model building and evaluation:

| Publication                       | Study description                                            |
| :-------------------------------- | :----------------------------------------------------------- |
| [Austin 1980](# 5 References)     | IV administration of 125 mg, 250 mg, 500 mg, and 900 mg as erythromycin lactobionate; single dose |
| [Barre 1987](# 5 References)      | IV administration of 500 mg as erythromycin lactobionate; single dose |
| [Berend 1979](# 5 References)     | berend 1979                                                  |
| [Birkett 1990](# 5 References)    | PO administration of 250 mg as enteric-coated capsules containing pellets of erythromycin base; single dose |
| [DiSanto 1981](# 5 References)    | PO administration of 500 mg as unprotected tablets containing erythromycin base, as film-coated tablets containing erythromycin base, as enteric-coated tablets containing erythromycin base and as film-coated tablets containing erythromycin stearate; single and multiple dose |
| [Huppertz 2011](# 5 References)   | IV administration of 1000 mg as erythromycin lactobionate; single dose |
| [Iliopoulou 1982](# 5 References) | PO administration of 500 mg as film-coated tablet containing erythromycin stearate; multiple dose |
| [Josefsson 1982](# 5 References)  | PO administration of 500 mg as film-coated tablet containing erythromycin stearate and 250 mg, 500 mg, 1000 mg as enteric coated capsules containing pellets of erythromycin base; single dose |
| [Kavi 1988](# 5 References)       | PO administration of 500 mg as film-coated tablet containing erythromycin stearate; single dose |
| [Kivistö 1997](# 5 References)    | PO administration of 500 mg as enteric-coated capsules containing erythromycin base; multiple dose |
| [Kroboth 1982](# 5 References)    | PO administration of 500 mg as enteric-coated tablets containing erythromycin base; single dose |
| [Malmborg 1978](# 5 References)   | PO administration of 500 mg as film-coated tablet containing erythromycin stearate; multiple dose |
| [Miglioli 1990](# 5 References)   | PO administration of 1000 mg erythromycin stearate; multiple dose |
|                                   |                                                              |
| [Pasic 1987](# 5 References)      | IV administration of 300 mg as erythromycin lactobionate; single dose |
| [Posti 1983](# 5 References)      | PO administration of 500 mg as film-coated tablets containing erythromycin stearate, as enteric-coated tablets containing erythromycin base, and as enteric-coated tablets containing erythromycin stearate; single dose |
| [Schreiner 1984](# 5 References)  | PO administration of 500 mg as film-coated tablets containing erythromycin stearate and as enteric-coated capsule containing pellets of erythromycin base; single dose |
| [Sun 2010](# 5 References)        | IV administration of 125 mg and PO administration of 250 mg (salt and formulation type not specified); single dose |
| [Yakatan 1980](# 5 References)    | PO administration of 250 mg as film-coated tablet containing erythromycin stearate, as enteric-coated tablet containing erythromycin base, and as enteric-coated capsules containing erythromycin estolate; single and multiple dose |

